115841-09-3

中文名称丹酚酸C

英文名称 Salvianolicacid C

CAS 115841-09-3

分子式 C26H20O10

分子量 492.43

MOL 文件 115841-09-3.mol

更新日期 2024/04/29 17:26:30

115841-09-3 结构式

基本信息物理化学性质应用领域常见问题列表

基本信息

中文别名

丹酚酸C
丹参酚酸C
丹酚酸C对照品,
丹酚酸C(标准品)
丹酚酸C(丹参酚酸C)

英文别名

Salvianolicacid C
(2R)-3-(3,4-Dihydroxyphenyl)-2-({(2E)-3-[2-(3,4-dihydroxyphenyl)- 7-hydroxy-1-benzofuran-4-yl]-2-propenoyl}oxy)propanoic acid
Benzenepropanoic acid, a-[[(2E)-3-[2-(3,4-dihydroxyphenyl)-7-hydroxy-4-benzofuranyl]-1-oxo-2-propen-1-yl]oxy]-3,4-dihydroxy-,(aR)-
Benzenepropanoic acid, α-[[(2E)-3-[2-(3,4-dihydroxyphenyl)-7-hydroxy-4-benzofuranyl]-1-oxo-2-propen-1-yl]oxy]-3,4-dihydroxy-, (αR)-
(alphaR)-alpha-[[(2E)-3-[2-(3,4-Dihydroxyphenyl)-7-hydroxy-4-benzofuranyl]-1-oxo-2-propen-1-yl]oxy]-3,4-dihydroxybenzenepropanoic acid

所属类别

生物化工：提取物

物理化学性质

外观性状白色结晶粉末，可溶于甲醇、乙醇、DMSO等有机溶剂，来源于丹参。

沸点844.2±65.0 °C(Predicted)

密度1.570

储存条件Inert atmosphere,2-8°C

溶解度Soluble in methanol and water

酸度系数(pKa)2.76±0.10(Predicted)

形态粉末

颜色黄色

应用领域

用途1

用于含量测定/鉴定/药理实验等。
药理药效:具有一定抗氧化、保护脑组织细胞损伤、保护心脑血管系统和抗HIV作用。

用途2

丹酚酸C 1.具有明显的抗血小板聚集作用。2.自由基清除剂。

常见问题列表

生物活性

Salvianolic acid C 是细胞色素 P4502C8 (CYP2C8) 的非竞争性抑制剂和细胞色素 P4502J2 (CYP2J2) 中等强度的混合抑制剂，其对 CYP2C8 和 CYP2J2 的 Ki 值分别为 4.82 μM 和 5.75 μM。

靶点

CYP2C8

4.82 μM (Ki)

CYP2J2

5.75 μM (Ki)

体外研究

Salvianolic acid C is a noncompetitive CYP2C8 inhibitor and a moderate mixed inhibitor of CYP2J2, with K _i s of 4.82, 5.75 μM for CYP2C8 and CYP2J2, respectively. 1 and 5 μM Salvianolic acid C (SalC) could significantly inhibit the NO production induced by LPS. Salvianolic acid C decreases the expression of iNOS significantly. Salvianolic acid C inhibits LPS-induced TNF-α, IL-1β, IL-6 and IL-10 overproduction. Salvianolic acid C inhibits LPS-induced NF‑κB activation. Salvianolic acid C also increases the expression of Nrf2 and HO-1 in BV2 microglial cells.

体内研究

Salvianolic acid C (20 mg/kg) treatment could significantly decrease the escape latency. In addition, SalC (10 and 20 mg/kg) treatment significantly increase the platform crossing number compared with the LPS model group. Systemic administration of Salvianolic acid C down regulates the brain TNF-α, IL-1β and IL-6 levels compared with the model group. The iNOS and COX-2 levels in rat brain cortex and hippocampus are higher than that in the control group, while Salvianolic acid C treatment significantly down regulates the cortex and hippocampus regions. Salvianolic acid C (5, 10 and 20 mg/kg) treatment dose-dependently increases the p-AMPK, Nrf2, HO-1 and NQO1 levels in rat brain cortex and hippocampus.